Martin Robert C G, Scoggins Charles R, Ross Merrick I, Reintgen Douglas S, Noyes R Dirk, Edwards Michael J, McMasters Kelly M
The Department of Surgery, University of Louisville, James Graham Brown Cancer Center, 315 East Broadway, Rm 313, Louisville, KY 40202, USA.
Am J Surg. 2005 Dec;190(6):913-7. doi: 10.1016/j.amjsurg.2005.08.020.
In the era of sentinel lymph node (SLN) biopsy, there has been concern that manipulation, injection, and massage of intact primary melanomas (after incisional or shave biopsy) could lead to an artifactual increased rate of SLN micrometastases or an actual increased risk of recurrence. The aim of this study was to evaluate the difference in the incidence of SLN metastasis, locoregional recurrence (LRR), disease-free survival (DFS), distant disease-free survival (DDFS), or overall survival (OS) for patients who undergo excisional versus incisional versus shave biopsy.
Analysis of database from a multicenter prospective randomized study from centers across the United States and Canada. Eligible patients were 18 to 71 years old, with cutaneous melanoma > or = 1.0 mm Breslow thickness. All patients underwent SLN biopsy using blue dye and radioactive colloid injection. SLNd were evaluated by serial histological sections with S100 immunohistochemistry. Statistical analysis was performed using univariate and multivariate analyses with a significance level of P < .05; survival analysis was performed by the Kaplan-Meier method with the log-rank test.
A total of 2,164 patients were evaluated; 382 patients were excluded for lack of biopsy information. Positive SLNs were found in 220 of 1,130 (19.5%), 58 of 281 (20.6%), and 67 of 354 (18.9%) of patients with excisional, incisional, or shave biopsy, respectively (no significant difference). There were significant differences among the 3 biopsy types in ulceration (P = .018, chi2) and regression (P = .022, chi2); there were no differences in age, gender, Breslow thickness, Clark level, lymphovascular invasion, tumor location, or histologic subtype. Biopsy type did not significantly affect LRR, DFS, DDFS, or OS.
The concern that incomplete excision of primary melanomas may result in an increased incidence of SLN micrometastases, artifactual or real, is unfounded. Similarly, there is no evidence that biopsy type adversely affects locoregional or distant recurrence. Although shave biopsy is generally discouraged because it may lead to inaccurate tumor thickness measurements, it does not appear to affect overall patient outcome.
在前哨淋巴结(SLN)活检时代,人们一直担心对完整的原发性黑色素瘤(在切除活检或削除活检后)进行操作、注射和按摩可能会导致前哨淋巴结微转移率人为增加或实际复发风险增加。本研究的目的是评估接受切除活检、切除活检和削除活检的患者在前哨淋巴结转移发生率、局部区域复发(LRR)、无病生存期(DFS)、远处无病生存期(DDFS)或总生存期(OS)方面的差异。
分析来自美国和加拿大各中心的一项多中心前瞻性随机研究的数据库。符合条件的患者年龄在18至71岁之间,皮肤黑色素瘤Breslow厚度≥1.0mm。所有患者均使用蓝色染料和放射性胶体注射进行前哨淋巴结活检。通过S100免疫组织化学对前哨淋巴结进行连续组织学切片评估。采用单因素和多因素分析进行统计学分析,显著性水平为P<.05;采用Kaplan-Meier方法和对数秩检验进行生存分析。
共评估了2164例患者;382例患者因缺乏活检信息而被排除。接受切除活检、切除活检和削除活检患者的前哨淋巴结阳性率分别为1130例中的220例(19.5%)、281例中的58例(20.6%)和354例中的67例(18.9%)(无显著差异)。三种活检类型在溃疡(P=.018,卡方检验)和消退(P=.022,卡方检验)方面存在显著差异;在年龄、性别、Breslow厚度、Clark分级、淋巴管侵犯、肿瘤位置或组织学亚型方面无差异。活检类型对局部区域复发、无病生存期、远处无病生存期或总生存期无显著影响。
原发性黑色素瘤切除不完全可能导致前哨淋巴结微转移发生率增加(人为或实际)的担忧是没有根据的。同样,没有证据表明活检类型会对局部区域或远处复发产生不利影响。虽然一般不鼓励削除活检,因为它可能导致肿瘤厚度测量不准确,但它似乎不会影响患者的总体预后。